We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Psychedelics – Products

World's First Ketamine Treatment Study for a Range of Behavioral Addictions Completed content piece image
Product News

World's First Ketamine Treatment Study for a Range of Behavioral Addictions Completed

Awakn Life Sciences Corp. announced today the completion of the world's first ketamine treatment study for behavioral addictions.
MAPS and Wesana Health Resume Final Negotiations content piece image
Product News

MAPS and Wesana Health Resume Final Negotiations

Analysis indicates viability of research pathway for MDMA-assisted therapy to treat symptoms associated with traumatic brain injury.
Wesana Health Commits Funding of $1.5 Million To Support MAPS’ Research Pipeline content piece image
Product News

Wesana Health Commits Funding of $1.5 Million To Support MAPS’ Research Pipeline

Wesana Health announced its commitment to fund an initial US $1.5 million to assess the viability of Multidisciplinary Association for Psychedelic Studies (MAPS) MDMA-assisted therapy to treat traumatic brain injury (TBI).
Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling Addiction  content piece image
Product News

Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling Addiction

Awakn Life Sciences Corp. has announced that it has received ethical committee approval and has initiated recruitment for the first-ever study investigating ketamine in gambling addiction.
Origin Therapeutics Launches To Fund Emerging Psychedelics Companies   content piece image
Product News

Origin Therapeutics Launches To Fund Emerging Psychedelics Companies

Origin Therapeutics Holdings Inc. an actively managed investment issuer focused on making equity investments in psychedelics-related companies, is pleased to announce its launch.

The Potential of Psychedelic Medicine to Transform Mental Health Treatment content piece image
Whitepaper

The Potential of Psychedelic Medicine to Transform Mental Health Treatment

Learn about the focus of current psychedelic research efforts and where the most promising progress is being made in this exciting area of drug discovery and development.
New Psychedelic Company Combines Neuroscience & Ceremonial Healing content piece image
Product News

New Psychedelic Company Combines Neuroscience & Ceremonial Healing

Dimensions Health Centres, a psychedelic treatment company, have officially announced the company formation and subsequent closure of an initial, oversubscribed round of funding.
Havn Life Sciences To Supply Psychedelics to Clinical Studies Focused on Veterans and PTSD content piece image
Product News

Havn Life Sciences To Supply Psychedelics to Clinical Studies Focused on Veterans and PTSD

Havn Life Sciences Inc. a biotechnology company, announced it has signed a Memorandum of Agreement (“MOA”) with the international veterans organization, Heroic Hearts Project.
CYBIN Signs Definitive Agreement to Acquire Adelia Therapeutics content piece image
Product News

CYBIN Signs Definitive Agreement to Acquire Adelia Therapeutics

Cybin Inc. today announced the signing of a definitive agreement to acquire 100% of the shares in Adelia Therapeutics Inc.
Havn Life Launches to Develop Psilocybin Products for Research content piece image
Product News

Havn Life Launches to Develop Psilocybin Products for Research

Havn Life is a biotechnology company aimed at improving cognitive performance through the standardized extraction of psychoactive compounds and the development of natural health care products from novel compounds.
Advertisement